Cadila Healthcare plans to launch molecule for diabetes dyslipidemia: Report

Cadila Healthcare, part of the ZydusCadila group, is reportedly planning to launch an indigenously developed molecule for diabetes dyslipidemia, which is expected to be called Saroglitizar. The company has been working on a new molecule since 2004. At present, the company has several molecules under its research pipeline which it hopes to bring to the market.

Recently, Zydus Cadila received tentative approval from USFDA for Doxepin Hcl tablets in the strengths of 3 mg and 6 mg. The estimated sale in 2012 as per IMS for Doxepin Hcl, which falls in the neuropsychiatry segment, was $15.5 million.